by The anti-inflammatory drugs market consists of a diverse range of products including corticosteroids, NSAIDs and biologics that are used to treat conditions of inflammation and pain caused by injuries, arthritis and other disorders. Anti-inflammatory medications work by reducing hormones that cause inflammation and swelling like prostaglandins. They provide effective relief from symptoms of inflammation related diseases like arthritis, tendinitis and bursitis. The global demand for anti-inflammatory drugs is rising primarily due to the increasing incidence of chronic inflammatory conditions such as rheumatoid arthritis and osteoarthritis attributed to aging population and obesity epidemic. According to some estimates, over 54 million Americans suffer from some form of arthritis. The growing prevalence of arthritis and related joint disorders drives the need for long term anti-inflammatory treatment options for pain management.
The global Anti-Inflammatory Drugs Market is estimated to be valued at US$ 102248.44 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the anti-inflammatory drugs market is the rise of biologics which provide targeted treatment strategies. Biologics such as Humira, Enbrel and Remicade have revolutionized the treatment of inflammatory conditions. They selectively block TNF-α and IL pathways involved in inflammation. Compared to traditional NSAIDs, biologics offer superior efficacy and safety profile. Their adoption continues to grow at a favorable rate driven by favorable clinical outcomes. Another trend is the shift towards development of anti-inflammatory drugs with novel mechanisms of action to address the unmet need of patient populations that do not respond to existing therapies or have experienced side effects. There is an ongoing research on small molecule inhibitors that can block specific inflammatory pathways with better selectivity.
Porter’s Analysis
Threat of new entrants: The anti-inflammatory drugs market has significant entry barriers such as high R&D costs and strict regulatory approvals. This reduces the threat of new entrants.
Bargaining power of buyers: Large pharmaceutical companies have significant bargaining power over smaller buyers due to their extensive product portfolios and strong brands. However, availability of generic alternatives provides options to buyers.
Bargaining power of suppliers: Major players control key raw material supply and have moderate bargaining power over suppliers due to their large scale of operations and established supply chains.
Threat of new substitutes: Alternate treatment options like stem cell therapy and biologics pose potential threats, however anti-inflammatory drugs remain first line of treatment for many indications.
Competitive rivalry: The market has few large players and many small to mid-sized companies. Strong competition exists in terms of pricing, brands, and new product development.
Key Takeaways
The Global Anti-Inflammatory Drugs Market Demand is expected to witness high growth over the forecast period supported by the rising prevalence of chronic diseases, growing geriatric population and new product launches. The global Anti-Inflammatory Drugs Market is estimated to be valued at US$ 102248.44 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030.
North America is anticipated to dominate the market during the forecast period owing to increasing healthcare spending and large patient pool seeking better treatment options. However, Asia Pacific is expected to grow at fastest pace due to improving access to healthcare in emerging countries like China and India.
Key players operating in the anti-inflammatory drugs market are Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy€TMs Laboratories. Major players are focusing on new product innovations and mergers & acquisitions to strengthen their positions in the market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
